These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 23276502

  • 1. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1.
    Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, Kong JC, Seol JG, Kang SH.
    Int J Antimicrob Agents; 2013 Feb; 41(2):156-61. PubMed ID: 23276502
    [Abstract] [Full Text] [Related]

  • 2. A Novel Chimeric Endolysin with Antibacterial Activity against Methicillin-Resistant Staphylococcus aureus.
    Haddad Kashani H, Fahimi H, Dasteh Goli Y, Moniri R.
    Front Cell Infect Microbiol; 2017 Feb; 7():290. PubMed ID: 28713777
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
    Park YS, Shin WS, Kim SK.
    J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
    [Abstract] [Full Text] [Related]

  • 4. Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.
    Kim NH, Park WB, Cho JE, Choi YJ, Choi SJ, Jun SY, Kang CK, Song KH, Choe PG, Bang JH, Kim ES, Park SW, Kim NJ, Oh MD, Kim HB.
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038042
    [Abstract] [Full Text] [Related]

  • 5. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC, Foster-Frey J, Donovan DM.
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [Abstract] [Full Text] [Related]

  • 6. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.
    Knaack D, Idelevich EA, Schleimer N, Molinaro S, Kriegeskorte A, Peters G, Becker K.
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):362-368. PubMed ID: 30554844
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model.
    Bae JY, Jun KI, Kang CK, Song KH, Choe PG, Bang JH, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD.
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670417
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme.
    Son JS, Lee SJ, Jun SY, Yoon SJ, Kang SH, Paik HR, Kang JO, Choi YJ.
    Appl Microbiol Biotechnol; 2010 May; 86(5):1439-49. PubMed ID: 20013118
    [Abstract] [Full Text] [Related]

  • 10. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ.
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 12. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [Abstract] [Full Text] [Related]

  • 13. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
    Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.
    Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
    [Abstract] [Full Text] [Related]

  • 14. Extracellular and intracellular bactericidal activities of XF-70 against small-colony variant hemB mutants of meticillin-susceptible and meticillin-resistant Staphylococcus aureus.
    Vaudaux P, Huggler E, Rhys-Williams W, Love WG, Lew DP.
    Int J Antimicrob Agents; 2011 Jun; 37(6):576-9. PubMed ID: 21414759
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.
    Rouse MS, Rotger M, Piper KE, Steckelberg JM, Scholz M, Andrews J, Patel R.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3187-91. PubMed ID: 16048923
    [Abstract] [Full Text] [Related]

  • 16. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
    Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM.
    J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
    [Abstract] [Full Text] [Related]

  • 17. P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.
    Gupta R, Prasad Y.
    Curr Microbiol; 2011 Jul; 63(1):39-45. PubMed ID: 21519800
    [Abstract] [Full Text] [Related]

  • 18. In vitro biofilm formation and bactericidal activities of methicillin-resistant Staphylococcus aureus clones prevalent in Korea.
    Cha JO, Park YK, Lee YS, Chung GT.
    Diagn Microbiol Infect Dis; 2011 May; 70(1):112-8. PubMed ID: 21398072
    [Abstract] [Full Text] [Related]

  • 19. Preliminary treatment of bovine mastitis caused by Staphylococcus aureus, with trx-SA1, recombinant endolysin of S. aureus bacteriophage IME-SA1.
    Fan J, Zeng Z, Mai K, Yang Y, Feng J, Bai Y, Sun B, Xie Q, Tong Y, Ma J.
    Vet Microbiol; 2016 Aug 15; 191():65-71. PubMed ID: 27374909
    [Abstract] [Full Text] [Related]

  • 20. High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus.
    Zhang Y, Teng D, Mao R, Wang X, Xi D, Hu X, Wang J.
    Appl Microbiol Biotechnol; 2014 Jan 15; 98(2):681-94. PubMed ID: 23624708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.